A phase I study of the CDK4/6 inhibitor in pediatric patients with malignant rhabdoid tumors, neuroblastoma, and other solid tumors, displays an acceptable safety profile, dose-dependent pharmacokinetic characteristics, and preliminary signs of tumor stabilization [168]. This evidence concerns the gene CDK4 and neuroblastoma.